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1  | INTRODUC TION
This paper is co-authored by researchers and two patient and pub-
lic involvement (PPI) group members from the National Institute 
for Health Research (NIHR)-funded Community pharmacy: 
Highlighting Alcohol use in Medication aPpointments-1 (CHAMP-1) 
5-year research programme. The aim of NIHR Programme Grants 
for Applied Research (PGfAR) is to deliver research findings that 
will lead to clear and identifiable patient benefits. As part of this, 
the NIHR expects active involvement of patients and the pub-
lic in the research activities of the programme, working with the 
research team, and not just their inclusion as ‘subjects’ of the 
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Abstract
Background: Patient and public involvement and co-production are widely used, but 
nevertheless contested concepts in applied health research. There is much confu-
sion about what they are, how they might be undertaken and how they relate to 
each other. There are distinct challenges and particular gaps in public involvement 
in alcohol research, especially when the study focus is on health matters other than 
alcohol dependence.
Objective: To explore how patient and public involvement and co-production have 
been interpreted and applied within a multi-disciplinary research programme in the 
development of a complex intervention on alcohol and medicine use in community 
pharmacies.
Design: The paper presents the authors' critical reflection on a grounded example of 
how public involvement concepts have been translated into practice in the interven-
tion development phase of a publicly funded research programme, noting its impact 
on the programme to date.
Discussion: Co-production adds another layer of complexity in the development of 
a complex intervention. The research planning requirements for publicly funded re-
search circumscribe the possibilities for co-production, including impacting on the 
possibility of stability and continuity over time.
K E Y W O R D S
alcohol, community pharmacy, complex interventions, co-production, medicines review, 
patient and public involvement
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research. Through critical reflection on a grounded example, the 
intervention development phase of this programme of applied 
health research, the paper identifies some of the challenges and 
benefits of operationalizing co-production and PPI in developing 
a complex intervention which features the sensitive topic of alco-
hol consumption. The paper examines how PPI and co-production 
concepts have been interpreted and applied from the pre-appli-
cation stage to the embedded research studies conducted for 
intervention development. The paper bridges a knowledge gap 
between funder calls for PPI and co-production and clarity on how 
to apply such principles in practice. While acknowledging the con-
siderable challenges, the authors make a case for the importance 
of including patients and the public in the production of alcohol, 
and complex interventions research.
2  | BACKGROUND
2.1 | The shift from PPI to co-production
The NIHR in England and the Netherlands Organisation for Health 
Research and Development (ZonMW) were identified as having, 
‘the most extensive involvement of members of the public’ in a sur-
vey conducted by authors concerned about avoidable waste in the 
production and reporting of research evidence.1 The authors argue 
that public involvement in research matters because public fund-
ing of research does not relate well to disease burden, certain areas 
get disproportionate amounts of attention, there is poor transpar-
ency, and most studies conducted ignore questions and outcomes 
of importance to patients, carers and health professionals leading to 
‘avoidable waste.’2 Others have argued that decisions about research 
priorities need to involve a greater diversity of perspectives because 
the pharmaceutical and biotechnology sectors have dominated the 
health research agenda, and research on the social, environmental, 
digital and behavioural determinants of health required to improve 
National Health Service (NHS) services, public health and social care 
has been under-resourced.3
The NIHR PPI involvement imperative has, unsurprisingly, led to 
an increase in the levels of PPI activity in NIHR-funded studies, fol-
lowed by calls for better reporting in order to achieve an empirically 
and theoretically informed understanding of the types, quality and 
impacts of the involvement activity being produced.4-6 The extent, 
quality and impact of the reporting of PPI have been inconsistent, 
and understandings and practices of PPI have been criticized as to-
kenistic and ‘top-down.’5,7
A 2015 strategic review of NIHR PPI suggested co-production, 
‘as a means of evolving and improving public involvement in re-
search,’ recommending the adoption of co-production principles to 
foster partnership, reciprocity and openness.8-10 The review iden-
tified the potential for co-production to add value, but there has 
been uncertainty about the meaning of the concept, and confusion 
about how to actually organize and deliver it in practice.11 INVOLVE, 
the advisory group funded by the NIHR to support active public 
involvement, published guidance as, ‘a first step in moving toward 
clarity about what we mean by co-producing research,’ (p6). This 
quickly sparked requests to clarify how to turn co-production theory 
into action.12 The guidance defines co-production as an approach in 
which:
… researchers, practitioners and the public work to-
gether, sharing power and responsibility from the start to 
the end of the project, including the generation of knowl-
edge. The assumption is that those affected by research 
are best placed to design and deliver it and have skills and 
knowledge of equal importance.
[10]
This assumption is clearly important and contains a number of 
elements, and thus deserves to be examined carefully. Paylor and 
McKevitt point out that the NIHR framing of co-production pres-
ents it as a more collaborative and egalitarian mode of involvement. 
They caution, however, that any such potential has to be understood 
in relation to the prevailing methodological and managerial con-
straints of funded health research.13 The traditions of participatory 
action research and co-operative inquiry, in which co-production 
methods have evolved over time, are at some considerable remove 
from those of contemporary applied health research where the 
randomized controlled trial (RCT) is methodologically dominant for 
intervention evaluation purposes, and where qualitative research 
per se has been considered low priority.14 There has been little re-
search on how researchers and others involved have responded to 
the imperative for more participatory knowledge production and 
how this translates into practice in complex research programmes 
within a contemporary academic context, ‘influenced by power and 
incentives.’15
2.2 | What exactly is co-production in health 
research?
The term co-production has its origins in work on urban govern-
ance in the United States in the late 1970s which was influenced by 
Lipsky's work on ‘street level bureaucrats.’16 In an early paper aimed 
at sharpening the definition of the concept, Parks et al17 describe 
co-production as the, ‘mixing of the productive efforts of regular 
and consumer producers.’ They drew on the work of Garn et al18 to 
argue that public services are to some extent inevitably co-produced 
because of the ways in which people work with, take up and adapt 
them. For example, policing relies on consent, co-operation and in-
formation from the communities it serves:
… the person being served (the client or consumer) is in-
evitably part of the production process, if there is to be 
any production whatsoever. Therefore, the resources, 
motivations, and skills brought to bear by the client or 
consumer are much more intimately connected with the 
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level of achieved output than in the case of goods pro-
duction. The output is always a jointly produced output.
[19]
Ostrom identifies co-production as a process of production, con-
tributed to by people who are not in the same organization, which in-
volves the transformation of a set of inputs into outputs. She describes 
the co-production process as one in which, ‘synergy between what a 
government does and what citizens do can occur.’19 She also acknowl-
edges the challenge of engineering such a process:
Designing institutional arrangements that help induce 
successful coproductive strategies is far more daunting 
than demonstrating their theoretical existence.
[20]
Such challenges, and the origins of the concept of co-production in 
contexts far from health research, may carry implications for applica-
tions in this area. Despite the positive framing by the NIHR, and the as-
pirational intent of the INVOLVE definition, Oliver et al20 recommend a 
cautious approach to co-production in contemporary health research 
because it carries a ‘dark side’ manifested in practical, personal and 
professional costs to participants.
The NIHR recommends the use of ‘4R’ criteria as the starting 
point for reporting on the impact of PPI on research: reach; rele-
vance; refinement and improvement and relationships.8,21 Reporting 
here is guided by the GRIPP2 checklist4 and will include the 4R as-
pects, with a particular focus on ‘refinement and improvement,’ that 
is the added value that public involvement brought to the first phase 
of the CHAMP-1 programme which used a ‘bottom-up’ approach to 
co-producing a complex intervention.
3  | DE VELOPING A COMPLE X 
INTERVENTION IN A CHALLENGING TOPIC 
ARE A
The CHAMP-1 programme is co-producing with the pharmacy pro-
fession and with patients and carers, a complex intervention for dis-
cussion of alcohol within community pharmacy-based medication 
reviews to be evaluated in a definitive RCT. This paper focuses on the 
objective for the first phase of the 5-year programme and develop-
ment of the intervention for use within established pharmaceutical 
services (Figure 1). Below, we explain why the sensitive nature of al-
cohol discussion makes such an intervention, and the process of its 
production, ‘complex’ and why the decision was made to ‘co-produce’.
3.1 | Alcohol as a sensitive subject
The majority of people have some experience of alcohol because it 
is very widely used and because its use impacts on people who do 
not drink alcohol themselves.22 For many, alcohol is associated with 
positive aspects of life, but alcohol is also linked to poor health in 
various and complex ways, including interactions with medicines, 23 
and it is implicated in social problems. It presents a degree of risk for 
all who use it.24,25 Yet, alcohol as a broad population health issue, 
outside of addiction services, is not an area with a substantive re-
cord of public involvement.26
Alcohol research has focused predominantly on particular popu-
lations and forms of problematized drinking that have stereotypical 
and highly stigmatized and stigmatizing foundations.27-29 It is also 
an area in which alcohol industry agendas are promoted heavily 
through marketing and social aspects organizations.30,31 In keeping 
with the avoidable waste agenda, the CHAMP-1 programme is build-
ing on an important body of pre-existing research,2 but, given the 
limited public discourse on alcohol health harms, is not an issue likely 
to be readily identified by the community/the public.
In a previous alcohol intervention trial in community phar-
macy, people who considered their drinking non-problematic did 
not consider the proposed intervention or the research topic to 
be relevant to them, largely because of the ways they thought 
about the nature of alcohol problems.32 Key challenges then for 
the CHAMP-1 programme are the lack of perception of personal 
health hazards due to alcohol outside of stereotypical concep-
tions of alcohol dependence and the sensitivity of any discussion 
about alcohol because of the stigmatization of alcohol-related 
problems.28,33 This sensitivity in talking about alcohol is linked to 
a sense of vulnerability to negative judgement. Alcohol research 
is a political arena in which science and public involvement and 
engagement can be skewed by vested commercial interests,34 and 
where improving communication of risk is key. Therefore, public 
advisors without vested commercial interests and with an open-
ness to consider varying forms of alcohol harms can potentially 
make a particularly valuable contribution.
3.2 | The complex intervention context
The approach to intervention development taken in the CHAMP-1 
programme was strongly informed by the investigators' experi-
ence of a previous community pharmacy trial of brief alcohol in-
terventions delivered by community pharmacists and the lessons 
learned in that study.35 In short, brief interventions that may be 
effective elsewhere, and there are grounds for uncertainty about 
their effectiveness (ie performance in ‘real-world’ conditions) 
rather than efficacy (performance in research contexts),36,37 were 
found not to work in the community pharmacy setting, probably 
because they placed demands on pharmacists to operate beyond 
the context of pharmaceutical practice.32,35 It was considered 
therefore to be more appropriate to integrate discussion of alco-
hol use into routine pharmaceutical practice, hence the rationale 
for a focus on medication reviews. The decision to co-produce the 
intervention with patients and with pharmacists was a fundamen-
tal change in orientation to intervention development from the 
previous trial.
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There was no one theory-based ‘off-the-shelf’ intervention ei-
ther available or likely to be effective, or judged adaptable to this 
context. Patients who participate in medication reviews live with 
long-term conditions. Building on previous experience and the input 
of patient advisors and a lay co-applicant, the application for NIHR 
programme funds thus proposed that the experiences and ideas 
patients have about these conditions and their treatment and man-
agement are crucial to understanding their receptivity to alcohol dis-
cussions. Drinking alcohol was viewed as posing a potential problem 
directly via its impact on health and well-being, and indirectly by 
potentially reducing adherence to, or the effectiveness of, pharma-
ceutical treatments.
The aim of the intervention is to help patients consider their 
own circumstances and make decisions about their own alcohol 
consumption and medication use. In order to achieve this, it aims 
to help pharmacists to develop skills and their practice in order to 
become more person-centred in consultations. This provides for 
an intervention opportunity with patients which might in turn help 
them to impact on their alcohol and medication management. The 
causal chain involves a series of steps, which may be accomplished 
more or less well in different interactions, and is therefore complex. 
It is difficult to be precise about the ‘active’ ingredients of an inter-
action between a community pharmacist and a person in a medicines 
review, and how this might relate to other factors to produce be-
haviour change and subsequent health outcomes for patients.38 The 
intervention developed therefore has to be flexible enough to adapt 
to the complexities of the systems in which it will be introduced.39
People have volition, their thinking, feelings and behaviour can 
be unpredictable and the contexts in which they live and inter-
act are dynamic, which means many factors can affect outcomes. 
Community pharmacists and community pharmacies will vary in 
how receptive they are to such attempts at introducing innova-
tions. There are guidelines on research involving complex inter-
ventions from the Medical Research Council which are currently 
being updated because of on-going developments in the field.40 
Informed by these guidelines, our funding application outlined a 
F I G U R E  1   Community pharmacy: 
Highlighting Alcohol use in Medication 
aPpointments (CHAMP)-1 research 
programme overview
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range of intervention development, feasibility and acceptability 
studies to prepare the intervention and trial design. The funded 
programme processes of intervention development and testing 
have been developed to fit pharmacy routine practice and re-
quire patient and public advisors to work with pharmacists and 
a multi-disciplinary research team using multiple methods within 
tight deadlines in a health system engaged in on-going change.41 
A programme PPI group, a pharmacy professional practice group 
(PPPG) and a policy advisory group (PAG) all advise on the de-
sign and conduct of the research and are represented on the pro-
gramme management group.
3.3 | Intervention development overview
The intervention development phase lasted 15 months and com-
prised a series of stages to develop versions of the intervention iter-
atively (see Figure 2). Phase 1 studies received NHS Health Research 
Authority research ethics approval (Yorkshire & the Humber—South 
Yorkshire Research Ethics Committee REC reference 17/YH/0406).
Each stage was concluded with ‘synthesis’ discussions by an 
intervention development subgroup of the wider research team in-
formed by PPI, PAG and PPPG meetings. Qualitative interview and 
ethnographic observation studies,33,42-44 and a scoping review of 
the literature on the particular services being studied45 informed 
the development of the first prototype of the intervention (version 
1). Interactive co-design workshops with patients and pharmacists 
were arranged to inform a review of this version (producing version 
2). Then, a study of how version 2 was conducted by pharmacists 
in practice informed version 3. Further consultation with the PPI 
and PPPG groups led to the production of version 4. Drawing on the 
CHAMP-1 PPI impact log, the process of establishing a PPI group 
and its particular input into refining and improving the research 
studies in the first phase of the programme is reported below.
4  | PPI IN THE CO -PRODUC TION 
PROCESS
4.1 | Establishing a PPI group
Patient involvement was initiated before drafting of the CHAMP-1 
funding application commenced in a preliminary process. PPI began 
with a discussion about pharmacists and alcohol advice on an ex-
isting online alcohol forum, followed by consultation with mem-
bers of an established pharmacy PPI group. Co-author Margaret 
Ogden (MO) was then recruited as a lay co-applicant via the NIHR/
INVOLVE People in Research website (peopl einre search.org). Three 
research team members, including MO, held a PPI event with five 
people with chronic conditions to further inform the development 
of the application prior to submission of the grant application (one 
person continued their membership after funding was awarded). 
The existing pharmacy PPI group was then consulted again about 
potential PPI roles and recruitment processes, with an invitation to 
join the CHAMP-1 group. The full application was originally submit-
ted approximately 17 months before the research programme actu-
ally began.
Once the programme was funded, the lay co-applicant became 
Chair of the PPI group, and PPI group recruitment was re-initiated 
via existing networks and support groups for long-term conditions 
(at whom medicine review services are targeted). We specified 
that applicants have experience of managing medication for a long-
term condition(s) and regular engagement with pharmacies. Other 
requirements were experience of drinking alcohol, and the willing-
ness and ability to discuss alcohol and work as part of a group. Some 
members also bring valuable carer perspectives. Quoting directly 
from MO who was a co-applicant and is now a co-investigator and 
Chair of the PPI group:
Recruitment of the PPI members has been carefully 
considered. The group developed gradually. Criteria 
for membership was defined specifically to reflect and 
closely mirror the research participant group. I believe 
this was crucial and has been pivotal to the project.
Recruitment was continuous (and remains so), reflecting changes 
in members' health and transport problems. By the end of the first 
phase of the programme (15-month duration), there were 10 active 
members of the PPI group (including the Chair) who regularly at-
tended meetings. The demographics of the current group at the end 
of phase one is shown in Table 1.
Patient and public involvement role descriptions and skills train-
ing provisions were developed when research staff were in post to 
support the process. PPI group members requested training to help 
develop their understanding of the research methods used in the 
programme. This is contract research, and there have been some 
changes in staff in the first phase of the programme and some gaps 
between appointments. PPI continuity has been provided by the 
Chair of the PPI group (MO) and the Programme Co-ordinator and 
co-author Duncan Stewart (DS). MO and co-author and represen-
tative from the PPI group, David Lewis (DL), have decision-making 
powers as members of the programme management group, which 
also includes pharmacists within the research team, along with 
non-pharmacist researchers. This group is chaired by the Principal 
Investigator and co-author Jim McCambridge (JM), and it oversees 
and is responsible for the conduct of the research. DL has found at-
tending and contributing to these meetings more of a challenging 
experience than the more informal and interactive PPI meetings. In 
DL's own words:
Opportunities to establish working relationships with 
people on the programme management group are limited 
because many members travel from other parts of the 
country or attend remotely by conference call. There is 
limited opportunity for pre-meeting preparation because 
of the hectic pace of the programme.
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In addition to these programme structures, the NIHR requires that 
the programme is overseen by an independent Programme Steering 
Committee (PSC), which meets at least annually to supervise and 
provide expert advice independent from the investigators on behalf 
of the NIHR and the NHS research sponsor. A member of the PSC is 
recruited (independent of the PPI group) to represent the interests of 
patients and the public.46
The INVOLVE co-production ideal of researchers and lay mem-
bers working together from the start to the end of the project like 
this is contingent on the stability of people's health, staff continuity 
and time to support the development of the PPI group while meeting 
other research targets. The potential to develop relationships and 
share power and responsibility is constrained within programme 
management arrangements that need to meet the requirements of 
the funder and the university and comply with research governance 
procedures. Decisions about the design of the research need to be 
made long before funding is awarded.
4.2 | PPI group role and working methods
The design of CHAMP-1 working PPI and co-production processes 
were informed by previous researcher and lay investigator experi-
ences of PPI and participatory research methods.47 The role of the 
PPI group is to provide a patient perspective throughout the life of 
the programme by advising the research team on the content and 
conduct of the research. Outcomes of this are recorded in a PPI im-
pact log (see Appendix 1). The group met four times in the interven-
tion development phase of the programme and is scheduled to meet 
twice a year thereafter. The content of the meetings is responsive 
to the research, and meetings are timed accordingly. Each member 
is paid for attending and preparing for each meeting, and travel ex-
penses are reimbursed. Members are paid at the same sessional rate 
for their work assisting in research preparation and delivery outside 
meetings. The PPI Chair and lay co-investigator views opportunities 
for deeper involvement in research development as the most inno-
vative part of the programme from her perspective. Quoting MO 
directly:
The testing out of topic guide and interviews by the PPI 
members [see below] has been the most innovative and 
inclusive mechanism of the PPI to date. It went beyond 
traditional channels of PPI such as reviewing and con-
tributing at meetings. It presented PPI members with 
opportunities to develop new skills – important for their 
personal development.
On-going waves of PPI recruitment present a challenge as experi-
ence, and familiarity with a complex programme is lost but also mean 
that the programme has benefited from ‘fresh’ perspectives over time. 
The programme has sought to engage members in meaningful rolling 
dialogue. This has been facilitated at meetings and also by research-
er-led email contact and updates between meetings to maintain mo-
mentum and an email discussion forum where members post relevant 
news about the research topic.
TA B L E  1   Patient and public involvement (PPI) group 
demographic data (including PPI chair)
Demographic characteristic
No. of members 
(total n = 10)
Sex
Men 6
Women 4
Age range (y)
45-54 3
55-64 3
65-71 2
Prefer not to disclose 2
Higher education
Secondary education 3
Higher education post-16 4
Undergraduate degree 2
Prefer not to disclose 1
Employment status
Retired 6
Semi-retired 1
Sickness, disability or unemployment benefits 2
Employed part-time 1
Ethnicity
White British or Irish 9
British South Asian 1
Sexuality
Heterosexual 8
Homosexual 1
Prefer not to disclose 1
Partner status
Married or partner 7
Divorced 1
Single 2
Alcohol frequency
4 or more times per week 3
2-3 times per week 6
2-4 times per month 1
No. of medications
8+ 1
6-7 4
4-5 2
2-3 2
1 1
Experience of medicines review (MUR/NMS) 6
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4.3 | Focusing on issues and dilemmas that arise for 
patients in medication and alcohol discussions
Our scoping review found that studies of medicine review services 
focused on the introduction and implementation of the services, 
with little attention to outcomes for patients.48 Consultations were 
reported to be short and characterized by limited engagement with 
patients and their health problems. The extent and nature of advice 
given was rarely examined. In order to learn from both pharmacists 
and patients about issues and dilemmas that arise in medication 
(and alcohol) discussions, it was important to get closer to every-
day medicines review practice. Exploratory observations found that 
pharmacists paid little attention to alcohol in the lifestyle section 
of medicines reviews or elsewhere in practice.42 Pharmacists said 
they found alcohol difficult to raise and to discuss, they felt under-
prepared and unconfident and that people were reluctant to talk 
about their drinking. Their main concern was that raising the topic 
would alienate their customers. These observational findings were 
discussed with the pharmacy advisory group. This formed the start-
ing point for successive stages of intervention development work. 
Figure 3 visualizes the PPI involvement in each of the studies and 
stages of the first-phase intervention development process, detailed 
below.
4.3.1 | Producing version 1 via qualitative studies
A patient interview study was conducted to better understand the 
views of people eligible for medicines reviews on the appropriate-
ness of alcohol as a subject for discussion in reviews.33 PPI mem-
bers helped in the design of this study by giving feedback on the 
interview schedule and by participating in and feeding back on the 
experience of taking part in pilot interviews. The PPI group also 
helped to design recruitment materials and a recruitment ‘pitch,’ that 
is how best to explain the study to potential participants. This input 
was informed by a PPI group discussion of their own experience of 
talking about alcohol with health professionals and what made these 
conversations feel comfortable, useful or the contrary. This included 
consideration of what it is that influences their own decisions to act 
on information. The group also discussed the most appropriate ter-
minology to describe people who use the pharmacy, given that com-
munity pharmacy is a commercial enterprise which variously uses 
the terms ‘customer,’ ‘client’ and ‘patient.’ There was no consensus 
on a standard preferred term because members of the group had 
issues with all, and with the term ‘pharmacy user.’ The decision was 
taken to keep the conversation rolling and to tailor the terminology 
used to the specific context of its use, with a preference for using 
‘people’ as far as possible.
The recruitment ‘pitch’ and leaflet produced with the PPI group 
made the interview study easier to explain concisely to people, 
and the recruitment target was achieved. This study produced rich 
data on how people use medicines and alcohol in everyday life, 
how they use the pharmacy, their experience of medicines reviews 
and their thoughts on talking about alcohol as part of a medicines 
review. It found that people were open to the idea of discussing 
alcohol with community pharmacists in the context of a medicines 
review if this was sensitively done and was routine, and the rele-
vance was clear to them. Nobody wanted to feel like they were 
being singled out to talk about their alcohol use.33 As in the prior 
trial that informed the programme bid, many people thought such 
a discussion was relevant only to those who had a ‘problem’ with 
alcohol in terms of addiction.32,33 They recalled having a pleasant 
‘chat’ with a pharmacist but there was poor recall of the content 
of their medicines reviews and low awareness of their purpose. 
Version 1 of a new intervention was developed partly based on 
this work. It was also informed by on-going analysis of the ratio-
nale, context, evidence and methods for intervention develop-
ment subsequent to the grant application and in discussion with 
all of the programme advisory groups.
4.3.2 | Producing version 2 via a co-design study
The key components of version 1 of the intervention were dis-
cussed with the PPI group along with ways to further develop it 
in subsequent intervention co-design workshops which took place 
with pharmacists and pharmacy users. A key component for dis-
cussion was a consultation guide for pharmacists. This included 
examples of ways to introduce the subject of alcohol comfortably 
while making its potential relevance clear. Members of the PPI 
group had a range of responses, especially to the scripted con-
tent. Discussion helped to refine this content and emphasized the 
importance of pharmacy-user participants at the workshop being 
able to hear the suggested phrases and consider them as part of 
an interaction, rather than reducing them to text. How speech was 
delivered in context would make a big difference to how the in-
tervention was perceived. Perfecting wording without a sense of 
interaction was inadequate for an intervention grounded in the 
evidence of ways to support people in exploration of their health, 
medicines and alcohol use.49
A member of the PPI group with design skills suggested the use 
of a ‘missing piece of the jigsaw puzzle’ symbol to represent alcohol 
as a missing element in medicines discussions. This was incorporated 
into the design of the slides used at the pharmacy-user co-design 
workshop. The full details of the design, methods and results of the 
pharmacy-user co-design workshop will be reported separately. The 
staff team at this workshop included co-author MO as co-host and 
observer, and co-author DL as a facilitator (having facilitation skills 
with groups talking about their own alcohol use). DL led one of the 
subgroups, and research team members led the others. All members 
of the workshop team commented on drafts of the schedule and 
facilitators took part in briefing and ‘de-bugging’ meetings, which 
further developed working relationships. Recruitment for the phar-
macy-user co-design workshop was challenging but was helped by 
building on the success of the PPI group's suggested recruitment 
recommendations for the patient interview study.
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4.3.3 | Producing version 3 via a feasibility study
The PPPG and PPI groups met to discuss the findings of pharmacist 
and pharmacy-user co-design workshops to decide whether there was 
proof of concept, that is, that there was evidence of the acceptability of 
the intervention, and to make further recommendations for develop-
ment. A joint meeting was proposed but was not feasible because of 
on-going difficulties for pharmacists attending meetings. These were 
therefore parallel processes where any differences in pharmacist and 
patient perspectives that arose were discussed by the research team. 
A key point of difference between pharmacists and people eligible for 
medicines reviews was that people wanted more information about 
the service and the opportunity to prepare for it, with an appoint-
ment made. However, pharmacists were passionate about the idea of 
pharmacy as a walk in service, arguing that this was what made phar-
macy unique and different from a GP surgery. Arranging appointments 
was therefore not an option. The PPI group meeting agreed that the 
co-design workshops provided proof of concept for the intervention. 
Ideas from the workshops about follow-up text messages and support-
ing leaflets were also discussed. The programme management group 
made decisions informed by both these processes and other research 
design and planning considerations.
The next stage was to run a small feasibility study to investigate 
how trial procedures and version 2 of the intervention could work 
in practice. Work to date indicated that practice development, in-
cluding a training component, should play a much larger part of the 
intervention than had been anticipated (this is separately reported). 
Two newly recruited PPI members volunteered to be participants in 
medicines review exercises and gave feedback on this experience 
during a training workshop for the feasibility study. These members 
felt pharmacists struggled to raise the subject and to link medicines 
and alcohol to a person's condition. They reported back to the wider 
PPI group who agreed that the way the subject of alcohol is brought 
up is crucial and that this required person-centred approaches to 
F I G U R E  3   Patient and public 
involvement input in intervention 
development phase 1
CHAMP-1 Research stages Involvement from patients and public                     
PPI Meeting 1 and individual  
members help design interview 
schedule, recruitment pitch and 
materials; pilot interviews
PPI Meeting 2 input on Version 1 
scripted content and co-design 
workshop planning
Pharmacy-users participate in 
co-design workshop
PPI co-applicant involvement
Consultation with existing PPI 
groups
Patient Interview Study
Perspectives on discussing alcohol 
in a medicines review with a 
pharmacist
Co-design Workshops
Pharmacy-user workshop to
explore the acceptability and 
feasibility of the proposed 
intervention and how it can be 
improved
Grant application
PPI co-applicant and PPI 
Programme Management Group 
Representative (PMG) provide 
further input on workshop plan 
Version 2
PPI co-applicant and PPI PMG 
Representative act as host and 
facilitator in the workshop
Ethnographic Observation Study
Feasibility Study
Pharmacist training and patient 
recruitment to investigate how a 
pilot trial and Version 2 could work
in practice PPI members participate as 
patients in training activities with 
pharmacists
PPI Meeting 3: PPI facilitators
provide feedback about co-
design workshop to PPI group. 
PPI members discuss findings of 
pharmacist and pharmacy-user 
workshops and key challenges to 
inform Version 3
Version 3
PPI Meeting 4: PPI members give
feedback on training day 
experiences; PPI group comment
on Version 3 to inform Version 4  Version 4
Version 1
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consultation practice. Most PPI advisors had been interested in 
self-empowerment as an important outcome from the outset; others 
started from the approach that ‘people need telling.’ There is now 
evidence-informed agreement in the PPI group that the interven-
tion will need to empower the practitioner in order to empower the 
person. Comments received on the resulting version 3 of the inter-
vention were used to create version 4, thereby ending the planned 
intervention development process.
5  | DISCUSSION
Critics have identified the NIHR approach to PPI and co-produc-
tion as highly instrumentalist, positioning these as means to solve 
a problem and produce a desired outcome.13 Complex processes 
can become abstract ‘things’ to be implemented and managed, 
decontextualized from the broader social, economic and politi-
cal contexts in which they operate.50 Implementation failure may 
be attributed to the reluctance of researchers to share power 
or recognize the value of lay knowledge, experience and skills.15 
However, the practical challenges involved in co-producing this 
programme of research are far more multi-layered than this, and 
it is important to acknowledge this if there is to be better under-
standing of the actual processes by which co-productive activity 
occurs.
Funding systems do not allow for meaningful co-production in 
advance of research studies beginning, and this places restrictions 
on how far and in which ways researchers can share power with 
the groups involved. It remains challenging to fit public involvement 
activities into the managerial logics and temporal pressures of the 
health research system and the market-driven neoliberal univer-
sity.51 There is good reason to question whether the institutional 
arrangements currently in place can support the ideals of PPI and 
co-production as portrayed in the progressive ideas of social move-
ments and to examine which tensions arise and how they play out in 
practice. The assumptions inherent in the INVOLVE definition may 
also be worth interrogating further within these contexts. Those 
championing user-led research continue to feel marginalized.52,53 
Space to be flexible and expansive is limited, as are time, outlets and 
incentives to evaluate and report PPI fully.4,54 Being serious about 
involvement means being serious about evaluation, which requires 
greater transparency.55
CHAMP-1 is a research programme using a range of research 
methods and intervention strategies. It seeks to use inputs from 
co-production, not for the ‘impression management’13 that can re-
sult from an imposed funding requirement, but to improve interven-
tion design and further the possibility of achieving person-centred 
outcomes, by including the knowledge of those who will deliver and 
receive the intervention. In our attempt to avoid waste and the ‘dark 
side’ of co-production,2,20 the strategy has been to operate trans-
parently, opening up a process of continual dialogue while giving 
critical consideration to the influences that inform the viewpoints 
and experiences being shared.
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APPENDIX 1
CHAMP-1 PATIENT AND PUBLIC INVOLVEMENT MEE TING IMPAC T LOG
Meeting Activity description Impact
Co-applicant Meeting
29/01/18
• PPI co-applicant helped developed interview guide • Interview guide altered/developed 
following PPI co-applicant involvement
PPI Meeting One
22/02/18
Introduction to CHAMP-1 PPI and Interview Study
• 2 PPI members participated in pilot interviews and gave interviewers 
feedback on the interview schedule
• Helped design flyers to recruit patients to interview study
• Discussed issues that may affect the consultation with intervention 
participants
• Suggested a PPI member role description would be useful
• Altered the flyer to contain University 
of York logo; changed colour scheme 
and pictures; and altered recruitment 
question wording
• Raised initial issues for the research 
team to consider—for example, feeling 
judged, ‘told off,’ suggestion of problem 
drinking
• PPI member role description made, 
sent to group and used in recruitment 
of new members
PPI Meeting Two
23/07/18
Feedback of interview findings; co-production training; MAC version 1 
introduction; and co-design workshop planning
Feedback from researchers:
• Changes to the flyer and how it was used to recruit people to 
interviews
• Interview findings
• Overview of CHAMP timeline
Key take away messages:
• Alcohol as a drug concept resonated with the group was seen as 
legitimate for pharmacist and relevant to patients
• Group suggested pitching alcohol as a drug concept to the workshop 
participants
• Members suggested sections of text that did not work well for them
• One member suggested a ‘Jigsaw’ visual idea for explaining the 
intervention purpose
• Discussed options for training—decided training will be incorporated 
into the meetings and be tailored to the group depending on the timing 
of the project
• Signed off on the role description and agreed for all to go through the 
recruitment process discussion about skills and experience with SM
• Group said: MAC has potential to build relationships, extending 
awareness of pharmacist expertise, a health professional ‘on your side’
Gave feedback on written scripted 
content of MAC guide
• MAC version 1 no longer included 
some text, for example ‘in ways that 
suit them’Helped researchers work out 
how to take the MAC guide into the 
co-design workshop:
• The team did not invite comments on 
written excerpts from the MAC script 
out of the context. The pharmacist's 
side of the consultation was read aloud 
to keep the context clear and to invite 
discussion of how and when things are 
said, as well as what is said.
• The team used ‘alcohol as a drug’ as the 
overall pitch for the intervention and 
provided an explanation for it
• The team used the Jigsaw image in 
the presentation and in visual aids 
throughout the workshop
Abbreviations: CHAMP, Community pharmacy: Highlighting Alcohol use in Medication aPpointments; PPI, patient and public involvement.
